Cetuximab is officially launched by Lupin

The first biosimilar created for Cetuximab just launched in India thanks to a strategic partnership between Enzene Biosciences and global pharmaceutical powerhouse Lupin Limited. This partnership represents an important turning point in the development of therapeutic alternatives and the promotion of innovation in the vital field of head and neck cancer therapy. A critical treatment option for patients with recurrent locoregional or metastatic diseases, cetuximab has been approved by the Drug Controller General of India (DCGI) for its efficacy in treating head and neck cancer, particularly Squamous Cell Carcinoma of the Head and Neck (SCCHN). A 100mg vial of cetuximab is readily available.

With a startling annual incidence of over 100,000 new cases, head and neck cancer poses a huge public health concern in India. Important parts of the head and neck, including as the oral cavity, pharynx, larynx, and sinuses, are affected by this cancer. Since the disease is frequently discovered in an advanced stage, finding a cure becomes more and more difficult. Because of this, head and neck cancer has a heavy burden that makes it difficult to treat it effectively and causes high fatality rates.

Rajeev Sibal, President – India Region Formulations, Lupin, commented on the introduction, saying, “The launch of first biosimilar Cetuximab underscores our steadfast devotion to improve patient outcomes and access to solutions. Through this partnership, we provide medical practitioners with a revolutionary and cost-effective solution that has the potential to significantly improve the lives of those dealing with this difficult disease.

More About Cetuximab

Cetuximab is a medication used in the treatment of certain types of cancer. It is a monoclonal antibody that specifically targets and blocks the activity of the epidermal growth factor receptor (EGFR), a protein found on the surface of cancer cells. By inhibiting EGFR, Cetuximab disrupts signaling pathways that promote cell growth, division, and survival, thereby slowing down or preventing the growth of cancer cells. It is primarily used in the treatment of metastatic colorectal cancer, as well as squamous cell carcinoma of the head and neck.

More About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

About Publisher

IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details Click here

For more Pharma related updates Click here

Leave a Reply


Enjoy this blog? Please spread the word :)

Follow by Email